Partial
Major Misalignment
Patient Risk:
Moderate
Summary
Several key dosing/administration and safety statements match the provided label excerpts (e.g., capsule not chewed, hallucinations/dyskinesia/somnolence risks). However, the label-supported initial dosing in levodopa-naïve patients and specific dose-frequency/interval guidance are not correctly represented, and some safety-risk claims are overstated or not fully anchored to the provided label text.
Category Scores
Accurate Statements
Rytary is formulated as capsules containing carbidopa and levodopa.
Label 11 DESCRIPTION: “RYTARY is a combination of carbidopa… and levodopa… in extended-release capsules for oral use.”
Rytary capsules should not be opened or chewed and should be swallowed whole.
Label 2.5 Administration: “Do not chew, divide or crush RYTARY capsules.” Also: “Swallow RYTARY whole with or without food.”
Dosages of Rytary may need to be adjusted over time based on a patient's response and tolerance.
Label 2.2: “Based upon individual patient clinical response and tolerability, the RYTARY dose may be increased…”
Healthcare providers will determine the appropriate dosage adjustments for Rytary.
Label 2.2: dose changes are described as clinician-directed (“The dosing frequency may be changed… if more frequent dosing is needed and if tolerated.” and “Based upon individual patient clinical response and tolerability…”).
Rytary carries risks including hallucinations.
Label 5.4: “There is an increased risk for hallucinations and psychosis in patients taking RYTARY…”
Rytary carries risks including dyskinesia.
Label 5.6: “RYTARY can cause dyskinesias…”
Unsupported Statements
Rytary is available in three dosage strengths: 145 mg, 195 mg, and 245 mg.
The provided label excerpts do not list the availability of strengths as 145 mg/195 mg/245 mg. Provided dosing strengths in the excerpt are in carbidopa/levodopa mg combinations (e.g., 36.25 mg/145 mg) but do not support this exact three-strength claim.
For patients new to carbidopa-levodopa therapy, the recommended starting dose for Rytary is one 145 mg capsule taken three times a day.
Label 2.2 for levodopa-naïve patients specifies an initial dose of 23.75 mg/95 mg three times daily for the first 3 days, then possible increase to 36.25 mg/145 mg three times daily on day 4.
Patients currently taking carbidopa-levodopa, the starting dose of Rytary is based on their current daily levodopa intake.
The provided excerpts do not describe such conversion logic. The excerpt states only that other carbidopa/levodopa product dosages are not interchangeable on a 1:1 basis (2.3), without supporting a 'based on daily levodopa intake' rule.
Patients already on carbidopa-levodopa should take Rytary capsules three times a day.
The excerpts do not provide a specific universal starting regimen for patients already on carbidopa-levodopa.
Rytary doses should be separated by at least 4 to 6 hours between each dose.
The provided label excerpts do not specify a minimum dose interval of 4–6 hours.
Rytary capsules should be taken orally three times daily.
While the levodopa-naïve titration section uses a three-times-daily frequency, the excerpt does not support this as a general instruction for all patients (e.g., the excerpt also notes frequency may change up to five times daily).
Rytary carries risks including dizziness.
The provided label excerpts list dizziness among common adverse reactions (6.1), which is label-supported as an adverse reaction. However, the label excerpt supports it as an adverse reaction occurrence, not necessarily as a specific 'risk' category; still, this is largely supported. Marked as unsupported due to framing inconsistency with provided excerpts.
Rytary carries risks including sudden onset of sleep.
Label 5.1 discusses falling asleep during activities of daily living and somnolence, but the provided excerpts do not mention 'sudden onset of sleep' wording.
Contradictions
High
AI Statement
For patients new to carbidopa-levodopa therapy, the recommended starting dose for Rytary is one 145 mg capsule taken three times a day.
Label Reference
Label 2.2: “recommended starting dosage… is 23.75 mg/95 mg taken orally three times a day for the first 3 days. On the fourth day… increased to 36.25 mg/145 mg taken three times a day.”
Important Omissions
For levodopa-naïve patients, the label-specific initial titration step (23.75 mg/95 mg TID for first 3 days, then increase to 36.25 mg/145 mg TID on day 4) was omitted/incorrectly replaced in the AI claims.
Importance:
High
Converting from immediate-release carbidopa-levodopa products is not 1:1 interchangeable (and the label excerpt does not support a simple 'based on current daily levodopa intake' rule).
Importance:
Moderate
Administration detail that high-fat/high-calorie meals may delay levodopa absorption by about 2 hours is not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The AI’s levodopa-naïve starting dose claim is contradicted by the label (day 1–3 should be 23.75/95 mg TID, not 36.25/145 mg). Other dosing/interval conversion assertions are not supported by provided label excerpts, which could lead to incorrect initiation or titration.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Major Misalignment
Primary Issue
Incorrect levodopa-naïve starting dose (145 mg capsule TID) contradicts the label titration schedule and missing/unsupported conversion and interval guidance.
Suggested Improvement
Replace the levodopa-naïve initiation claim with the label titration (23.75 mg/95 mg TID x first 3 days, then 36.25 mg/145 mg TID on day 4). Remove or rephrase unsupported conversion/in-between-dose interval claims, and ensure frequency guidance reflects label variability (up to five times daily if needed/tolerated).